In summary, GLP-1 analogues are mature clinical treatments for diabetes and obesity, with proven efficacy in reducing glycaemia, modestly reducing weight, and reducing cardiovascular events in people with type 2 diabetes at high risk of cardiovascular disease. This evidence concerns the gene GCG and cardiovascular disorder.